Literature DB >> 32363481

MLH1 intronic variants mapping to + 5 position of splice donor sites lead to deleterious effects on RNA splicing.

Tamara Alejandra Piñero1,2, Omar Soukarieh3, Marion Rolain3, Karin Alvarez4, Francisco López-Köstner4, Giovana Tardin Torrezan5, Dirce Maria Carraro5, Ivana Lucia De Oliveira Nascimento6, Thaís Ferreira Bomfim6, Taísa Manuela Bonfim Machado-Lopes6, Juliana Côrtes Freitas6,7, Maria Betânia Toralles6, Kiyoko Abe Sandes6, Benedito Mauro Rossi8, Samuel Aguiar Junior9, Joanna Meira10, Mev Dominguez-Valentin11,12, Pål Møller13, Carlos Alberto Vaccaro1,2, Alexandra Martins3, Walter Hernán Pavicic14,15.   

Abstract

Germline pathogenic variants in the DNA mismatch repair genes (MMR): MLH1, MSH2, MSH6, and PMS2, are causative of Lynch syndrome (LS). However, many of the variants mapping outside the invariant splice site positions (IVS ± 1, IVS ± 2) are classified as variants of unknown significance (VUS). Three such variants (MLH1 c.588+5G>C, c.588+5G>T and c.677+5G>A) were identified in 8 unrelated LS families from Argentina, Brazil and Chile. Herein, we collected clinical information on these families and performed segregation analysis and RNA splicing studies to assess the implication of these VUS in LS etiology. Pedigrees showed a clear pattern of variant co-segregation with colorectal cancer and/or other LS-associated malignancies. Tumors presented deficient expression of MLH1-PMS2 proteins in 7/7 of the LS families, and MSI-high status in 3/3 cases. Moreover, RNA analyses revealed that c.588+5G>C and c.588+5G>T induce skipping of exon 7 whereas c.677+5G>A causes skipping of exon 8. In sum, we report that the combined clinical findings in the families and the molecular studies provided the evidences needed to demonstrate that the three MLH1 variants are causative of LS and to classify c.588+5G>C and c.677+5G>A as class 5 (pathogenic), and c.588+5G>T as class 4 (likely-pathogenic). Our findings underline the importance of performing clinical and family analyses, as well as RNA splicing assays in order to determine the clinical significance of intronic variants, and contribute to the genetic counseling and clinical management of patients and their relatives.

Entities:  

Keywords:  Lynch syndrome; MLH1; Mismatch repair genes; Splicing assay; Splicing defect; Variants of unknown significance

Mesh:

Substances:

Year:  2020        PMID: 32363481     DOI: 10.1007/s10689-020-00182-5

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  4 in total

1.  Immunohistochemistry and RNA-sequencing have been useful in evaluating the pathological significance of a non-consensus site intronic variant in suspected cases of Lynch syndrome.

Authors:  Toshiya Nishikubo; Kaoru Masui; Fumikazu Koyama; Tomoko Uchiyama; Chiho Ohbayashi; Kazuo Tamura
Journal:  Int Cancer Conf J       Date:  2021-03-06

2.  RNA Analysis and Clinical Characterization of a Novel Splice Variant in the NSD1 Gene Causing Familial Sotos Syndrome.

Authors:  Olatz Villate; Hiart Maortua; María-Isabel Tejada; Isabel Llano-Rivas
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418

3.  Modeling a Novel Variant of Glycogenosis IXa Using a Clonal Inducible Reprogramming System to Generate "Diseased" Hepatocytes for Accurate Diagnosis.

Authors:  Guillem Garcia-Llorens; Sergi Lopez-Navarro; Teresa Jaijo; Jose V Castell; Roque Bort
Journal:  J Pers Med       Date:  2022-07-07

4.  Spectrum and Frequency of Tumors, Cancer Risk and Survival in Chilean Families with Lynch Syndrome: Experience of the Implementation of a Registry.

Authors:  Karin Álvarez; Paulina Orellana; Marjorie De la Fuente; Tamara Canales; Eliana Pinto; Claudio Heine; Benjamín Solar; Claudia Hurtado; Pål Møller; Udo Kronberg; Alejandro José Zarate; Mev Dominguez-Valentin; Francisco López-Köstner
Journal:  J Clin Med       Date:  2020-06-15       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.